A network meta-analysis of therapeutic outcomes after new image technology-assisted transurethral resection for non-muscle invasive bladder cancer: 5-aminolaevulinic acid fluorescence vs hexylaminolevulinate fluorescence vs narrow band imaging

BMC Cancer

Volumn 15, Issue 1, 2015, Pages

  Lee, Joo Yong ^a   Cho, Kang Su ^b   Kang, Dong Hyuk ^c   Jung, Hae Do ^a   Kwon, Jong Kyou ^d   Oh, Cheol Kyu ^d   Ham, Won Sik ^a   Choi, Young Deuk ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Yangpyeong Health Center   (South Korea)

^d Inje University College of Medicine   (South Korea)

Author keywords

Bayes theorem; Meta analysis; Narrow band imaging; Photochemotherapy; Urinary bladder neoplasms

Indexed keywords

AMINOLEVULINIC ACID; AMINOLEVULINIC ACID HEXYL ESTER; 5-AMINOLEVULINIC ACID HEXYL ESTER; PHOTOSENSITIZING AGENT;

ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CYSTOSCOPY; ENDOSCOPIC SURGERY; FLUORESCENCE IMAGING; HUMAN; IMAGE QUALITY; META ANALYSIS; NARROW BAND IMAGING; NON MUSCLE INVASIVE BLADDER CANCER; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; RECURRENCE RISK; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; TRANSURETHRAL RESECTION; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; COMPARATIVE STUDY; COMPUTER ASSISTED DIAGNOSIS; METABOLISM; PATHOLOGY; PROCEDURES; URINARY BLADDER NEOPLASMS;

AMINOLEVULINIC ACID; CYSTOSCOPY; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; NARROW BAND IMAGING; PHOTOSENSITIZING AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 84938063413     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-1571-8     Document Type: Article

References (36)

1. Bohle A, Jocham D, Bock PR. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol. 2003;169(1):90-5.
2. Oh KJ, Choi YD, Chung HS, Hwang EC, Jung SI, Kwon DD, et al. A novel transurethral resection technique for superficial flat bladder tumor: grasp and bite technique. Korean J Urol. 2015;56(3):227-32.
3. Jocham D, Witjes F, Wagner S, Zeylemaker B, van Moorselaar J, Grimm MO, et al. Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study. J Urol. 2005;174(3):862-6. discussion 866.
4. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.
5. Chung JH, Lee SW. Assessing the quality of randomized controlled urological trials conducted by korean medical institutions. Korean J Urol. 2013;54(5):289-96.
6. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557-60.
7. Fleiss JL. Analysis of data from multiclinic trials. Control Clin Trials. 1986;7(4):267-75.
8. Riedl CR, Daniltchenko D, Koenig F, Simak R, Loening SA, Pflueger H. Fluorescence endoscopy with 5-aminolevulinic acid reduces early recurrence rate in superficial bladder cancer. J Urol. 2001;165(4):1121-3.
9. Filbeck T, Pichlmeier U, Knuechel R, Wieland WF, Roessler W. Clinically relevant improvement of recurrence-free survival with 5-aminolevulinic acid induced fluorescence diagnosis in patients with superficial bladder tumors. J Urol. 2002;168(1):67-71.
10. Kriegmair M, Zaak D, Rothenberger KH, Rassweiler J, Jocham D, Eisenberger F, et al. Transurethral resection for bladder cancer using 5-aminolevulinic acid induced fluorescence endoscopy versus white light endoscopy. J Urol. 2002;168(2):475-8.
11. Babjuk M, Soukup V, Petrik R, Jirsa M, Dvoracek J. 5-aminolaevulinic acid-induced fluorescence cystoscopy during transurethral resection reduces the risk of recurrence in stage Ta/T1 bladder cancer. BJU Int. 2005;96(6):798-802.
12. Schumacher MC, Holmang S, Davidsson T, Friedrich B, Pedersen J, Wiklund NP. Transurethral resection of non-muscle-invasive bladder transitional cell cancers with or without 5-aminolevulinic Acid under visible and fluorescent light: results of a prospective, randomised, multicentre study. Eur Urol. 2010;57(2):293-9.
13. Stenzl A, Penkoff H, Dajc-Sommerer E, Zumbraegel A, Hoeltl L, Scholz M, et al. Detection and clinical outcome of urinary bladder cancer with 5-aminolevulinic acid-induced fluorescence cystoscopy: A multicenter randomized, double-blind, placebo-controlled trial. Cancer. 2011;117(5):938-47.
14. Dragoescu O, Tomescu P, Panus A, Enache M, Maria C, Stoica L, et al. Photodynamic diagnosis of non-muscle invasive bladder cancer using hexaminolevulinic acid. Rom J Morphol Embryo. 2011;52(1):123-7.
15. Hermann GG, Mogensen K, Carlsson S, Marcussen N, Duun S. Fluorescence-guided transurethral resection of bladder tumours reduces bladder tumour recurrence due to less residual tumour tissue in Ta/T1 patients: a randomized two-centre study. BJU Int. 2011;108(8 Pt 2):E297-303.
16. Stenzl A, Burger M, Fradet Y, Mynderse LA, Soloway MS, Witjes JA, et al. Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. J Urol. 2010;184(5):1907-13.
17. Geavlete B, Multescu R, Georgescu D, Jecu M, Stanescu F, Geavlete P. Treatment changes and long-term recurrence rates after hexaminolevulinate (HAL) fluorescence cystoscopy: does it really make a difference in patients with non-muscle-invasive bladder cancer (NMIBC)? BJU Int. 2012;109(4):549-56.
18. Karaolides T, Skolarikos A, Bourdoumis A, Konandreas A, Mygdalis V, Thanos A, et al. Hexaminolevulinate-induced fluorescence versus white light during transurethral resection of noninvasive bladder tumor: does it reduce recurrences? Urology. 2012;80(2):354-9.
19. Geavlete B, Multescu R, Georgescu D, Stanescu F, Jecu M, Geavlete P. Narrow band imaging cystoscopy and bipolar plasma vaporization for large nonmuscle-invasive bladder tumors--results of a prospective, randomized comparison to the standard approach. Urology. 2012;79(4):846-51.
20. Montanari E, de la Rosette J, Longo F, Del Nero A, Laguna P. Narrow-band imaging (NBI) and white light (WLI) transurethral resection of the bladder in the treatment of non-muscle-invasive bladder cancer. Arch Ital Urol Androl. 2012;84(4):179-83.
21. Naselli A, Introini C, Timossi L, Spina B, Fontana V, Pezzi R, et al. A randomized prospective trial to assess the impact of transurethral resection in narrow band imaging modality on non-muscle-invasive bladder cancer recurrence. Eur Urol. 2012;61(5):908-13.
22. Lee JY, Choi JH, Kim IK DJH, KH W, LK S, Yoon YE, et al. Recurrence rate of transurethral resection of bladder tumor using narrow band imaging: A randomized control trial, pilot study. J Urol. 2014;191(Supplement(4S):e240-1.
23. Goh AC, Lerner SP. Application of new technology in bladder cancer diagnosis and treatment. World J Urol. 2009;27(3):301-7.
24. Ku JH, Lerner SP. Strategies to prevent progression of high-risk bladder cancer at initial diagnosis. Curr Opin Urol. 2012;22(5):405-14.
25. Kausch I, Sommerauer M, Montorsi F, Stenzl A, Jacqmin D, Jichlinski P, et al. Photodynamic diagnosis in non-muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies. Eur Urol. 2010;57(4):595-606.
26. Lerner SP, Liu H, Wu MF, Thomas YK, Witjes JA. Fluorescence and white light cystoscopy for detection of carcinoma in situ of the urinary bladder. Urol Oncol. 2012;30(3):285-9.
27. Yuan H, Qiu J, Liu L, Zheng S, Yang L, Liu Z, et al. Therapeutic outcome of fluorescence cystoscopy guided transurethral resection in patients with non-muscle invasive bladder cancer: a meta-analysis of randomized controlled trials. PLoS One. 2013;8(9):e74142.
28. Zheng C, Lv Y, Zhong Q, Wang R, Jiang Q. Narrow band imaging diagnosis of bladder cancer: systematic review and meta-analysis. BJU Int. 2012;110(11 Pt B):E680-7.
29. Li K, Lin T, Fan X, Duan Y, Huang J. Diagnosis of narrow-band imaging in non-muscle-invasive bladder cancer: a systematic review and meta-analysis. Int J Urol. 2013;20(6):602-9.
30. Shen YJ, Zhu YP, Ye DW, Yao XD, Zhang SL, Dai B, et al. Narrow-band imaging flexible cystoscopy in the detection of primary non-muscle invasive bladder cancer: a "second look" matters? Int Urol Nephrol. 2012;44(2):451-7.
31. Isfoss BL. The sensitivity of fluorescent-light cystoscopy for the detection of carcinoma in situ (CIS) of the bladder: a meta-analysis with comments on gold standard. BJU Int. 2011;108(11):1703-7.
32. Mowatt G, N'Dow J, Vale L, Nabi G, Boachie C, Cook JA, et al. Photodynamic diagnosis of bladder cancer compared with white light cystoscopy: Systematic review and meta-analysis. Int J Technol Assess Health Care. 2011;27(1):3-10.
33. Lee JS, Lee SY, Kim WJ, Seo SI, Jeon SS, Lee HM, et al. Efficacy and safety of hexaminolevulinate fluorescence cystoscopy in the diagnosis of bladder cancer. Korean J Urol. 2012;53(12):821-5.
34. Rink M, Babjuk M, Catto JW, Jichlinski P, Shariat SF, Stenzl A, et al. Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature. Eur Urol. 2013;64(4):624-38.
35. Grimbergen MC, van Swol CF, Jonges TG, Boon TA, van Moorselaar RJ. Reduced specificity of 5-ALA induced fluorescence in photodynamic diagnosis of transitional cell carcinoma after previous intravesical therapy. Eur Urol. 2003;44(1):51-6.
36. Cheung G, Sahai A, Billia M, Dasgupta P, Khan MS. Recent advances in the diagnosis and treatment of bladder cancer. BMC Med. 2013;11:13.